Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNDX 
Syndax Pharmaceuticals Inc (SNDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.36
1 Year Target Price $36.36
| 9 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.1% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.27B USD | Price to earnings Ratio - | 1Y Target Price 36.36 |
Price to earnings Ratio - | 1Y Target Price 36.36 | ||
Volume (30-day avg) 12 | Beta 0.73 | 52 Weeks Range 8.58 - 22.50 | Updated Date 08/15/2025 |
52 Weeks Range 8.58 - 22.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-04 | When - | Estimate -1.01 | Actual -0.83 |
Profitability
Profit Margin - | Operating Margin (TTM) -182.71% |
Management Effectiveness
Return on Assets (TTM) -39.5% | Return on Equity (TTM) -113.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 801838627 | Price to Sales(TTM) 16.28 |
Enterprise Value 801838627 | Price to Sales(TTM) 16.28 | ||
Enterprise Value to Revenue 10.29 | Enterprise Value to EBITDA -105.26 | Shares Outstanding 86141904 | Shares Floating 77049588 |
Shares Outstanding 86141904 | Shares Floating 77049588 | ||
Percent Insiders 1.29 | Percent Institutions 123.86 |
Upturn AI SWOT
Syndax Pharmaceuticals Inc
Company Overview
History and Background
Syndax Pharmaceuticals Inc. was founded in 2005. It is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of cancer.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing therapies for cancer treatment.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company operates with a functional organizational structure, prioritizing research and development.
Top Products and Market Share
Key Offerings
- Revumenib: Revumenib is an oral menin inhibitor for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). Competitors include Novartis and Astellas Pharma. Market share for revumenib and estimated revenue from this drug is emerging due to FDA approval recently
- Axatilimab: Axatilimab is an anti-CSF-1R monoclonal antibody in development for chronic graft-versus-host disease (cGVHD). Competitors include Kadmon, now part of Sanofi, and Incyte. Market share data is limited as it is still in clinical trials and has not yet been FDA approved.
Market Dynamics
Industry Overview
The oncology drug market is a large and growing market, driven by increasing cancer incidence and advances in treatment options.
Positioning
Syndax is positioned as a company specializing in targeted therapies for specific cancer subtypes, aiming to address unmet needs in niche markets.
Total Addressable Market (TAM)
The total addressable market for oncology drugs is estimated to be in the hundreds of billions of dollars annually. Syndax is targeting specific AML and cGVHD segments within this larger market. TAM for revumenib target market is about 1B USD.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates
- Experienced management team
- Strong intellectual property position
Weaknesses
- Reliance on clinical trial outcomes
- Limited commercial infrastructure
- High cash burn rate
Opportunities
- Positive clinical trial results
- Strategic partnerships
- Expansion into new indications
Threats
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expiration
Competitors and Market Share
Key Competitors
- NVS
- MRK
- GILD
- INCY
- SNY
Competitive Landscape
Syndax faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its innovative therapies and focus on specific cancer subtypes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pipeline advancement and strategic collaborations.
Future Projections: Future growth is dependent on the success of Revumenib and Axatilimab. Analyst projections vary based on clinical trial outcomes and commercial potential.
Recent Initiatives: Recent initiatives include advancing revumenib and axatilimab through clinical trials, seeking regulatory approvals, and establishing partnerships for commercialization.
Summary
Syndax Pharmaceuticals is a development-stage biopharmaceutical company with promising drug candidates in oncology. Its success hinges on positive clinical trial results and regulatory approvals for its key assets, revumenib and axatilimab. The company's financial health is currently dependent on raising capital and strategic partnerships. Syndax faces significant competition from established pharmaceutical players and potential setbacks in clinical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Syndax Pharmaceuticals Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Syndax Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-03-03 | CEO & Director Mr. Michael A. Metzger M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 270 | Website https://syndax.com |
Full time employees 270 | Website https://syndax.com | ||
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.